[Pathogenetic role of moxonidine in the treatment of hypertension in postmenopausal women].
To assess efficacy of monotherapy with moxonidine in female patients with hypertension and climacteric syndrome. Twenty-four hour blood pressure monitoring was carried out in 32 women (mean age 52.3-/+5.2 years) before and after 28 days of monotherapy with moxonidine (0.2-0.4 mg). In 4 weeks the following significant changes were registered: lowering of systolic and diastolic blood pressures, decrease of blood pressure variability and rate of its morning rise, increase of 24-hour blood pressure index. This was accompanied by significant decrease of vascular peripheral resistance without changes of myocardial contractility. There were no significant changes of parameters of carbohydrate, lipid and purine metabolism. Moxonidine in women with hypertension and climacteric syndrome caused blood pressure lowering at the account of decreased total peripheral resistance and restoration of physiological blood pressure rhythm.